Eton Pharmaceuticals (ETON) said Thursday that the US Food and Drug Administration has extended the review deadline for Eaton's new drug application for ET-400, its proprietary patented formulation of hydrocortisone oral solution.
The new Prescription Drug User Fee Act goal date is May 28.
The FDA informed Eton that more time is needed to review additional information submitted in December. The new deadline reflects a standard three-month extension from the original date of Feb. 28.
"We do not expect this standard extension to significantly affect our internal 2025 revenue projections," Chief Executive Sean Brynjelsen said.
Price: 18.03, Change: -0.23, Percent Change: -1.23
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.